0B68 Aplin, Andrew E. - Thomas Jefferson University - Thomas Jefferson University
aea004

Andrew E. Aplin, PhD

Contact Dr. Aplin

Kimmel Cancer Center
233 S. Tenth Street, Suite 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. Adaptive resistance to RAF inhibitors in melanoma
  2. Resistance to RAF inhibitors revisited
  3. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors
  4. Erratum: Hippo: Hungry, hungry for melanoma invasion (Journal of Investigative Dermatology)
  5. Hippo: Hungry, hungry for melanoma invasion
  6. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma
  7. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors
  8. A statement on vemurafenib-resistant melanoma
  9. Meeting report: The future of preclinical mouse models in melanoma treatment is now.
  10. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells
  11. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
  12. Meeting report: The future of preclinical mouse models in melanoma treatment is now
  13. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells
  14. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor
  15. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
  16. Resistance to Chemotherapy. Short-Term Drug Tolerance and Stem Cell-Like Subpopulations.
  17. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
  18. The Yin-Yang of RAF inhibitors
  19. ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity
  20. Meeting report from the 2011 international melanoma congress, Tampa, Florida
0